Skip to main content

Table 2 Characteristics of bipolar patients with metabolic syndrome and hyperuricemia

From: Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder

Variable

Metabolic syndrome

Hyperuricemia

Yes (n = 135)

No (n = 183)

p

Yes (n = 86)

No (n = 232)

p

Age (years)

44.1 (12.5)

35.4 (12.6)

< 0.001

40.5 (13.4)

38.6 (13.0)

0.265

Male, n (%)

67 (49.6)

83 (45.4)

0.450

50 (56.8)

100 (43.5)

0.033

Education (years)

11.5 (3.6)

12.10 (3.4)

0.104

11.4 (3.2)

12.0 (3.5)

0.150

Smoker, n (%)

42 (31.1)

44 (24.0)

0.161

26 (29.5)

60 (26.1)

0.534

Married, n (%)

83 (61.5)

92 (50.3)

0.047

47 (53.4)

128 (55.7)

0.719

Illness duration (year)

15.9 (11.3)

9.9 (9.3)

< 0.001

14.25 (10.6)

11.9 (10.6)

0.013

Over weight, n (%)

85 (63.0)

60 (32.8)

< 0.001

52 (59.1)

93 (40.4)

0.003

Illness episode, n (%)

  

0.012

  

0.001

 Manic/hypomanic

91 (67.4)

104 (56.8)

 

68 (77.3)

127 (55.2)

 

 Depressive

31 (23.0)

69 (37.7)

 

14 (15.9)

86 (37.4)

 

 Mixed

5(3.7)

1 (0.5)

 

3 (3.4)

3 (1.3)

 

 Euthymic

8(5.9)

9(4.9)

 

3 (3.4)

14 (6.1)

 

BPD type II, n (%)

9 (6.7)

12 (6.6)

0.969

6 (6.8)

15 (6.5)

0.924

Antipsychotics use, n (%)

120 (88.9)

135 (73.8)

0.001

72 (81.8)

183 (79.6)

0.652

CPZ equivalents (mg/d)

344.7 (205.9)

297.7 (248.1)

0.030

3602 (209.8)

307.0 (236.1)

0.081

Mood stabilizer use, n (%)

118 (87.4)

144 (78.7)

0.044

74 (84.1)

188 (81.7)

0.662

  1. Data were mean ± SD unless otherwise indicated. BPD bipolar disorder, CPZ chlorpromazine